MedPath

Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study

Not Applicable
Recruiting
Conditions
Genicular Nerves
Peripheral Nerve Stimulation
Chronic Knee Pain
Interventions
Other: PNS therapy
Other: Placebo
Registration Number
NCT06004882
Lead Sponsor
M.D. Anderson Cancer Center
Brief Summary

To compare the effects of the following types of therapy on knee range of motion when given to patients with chronic knee pain:

* A standard steroid injection

* Peripheral nerve stimulation (PNS) therapy in combination with a standard steroid injection

* PNS therapy in combination with a placebo injection

Steroid injections are given directly into the knee joints and are considered to be the standard therapy for chronic knee pain. In this study, the injection will be made of the steroid drugs triamcinolone and bupivacaine.

Detailed Description

Primary Objectives:

* To compare the mean change in knee range of motion using goniometry from at 30 days (visit 2) from baseline among the three treatment arms.

Secondary Objectives:

* To compare the mean change in knee range of motion using goniometry at 60 days (visit 3) and 90 days (visit 4) from baseline among the three treatment arms.

* To compare changes in knee pain scores (NRS), WOMAC index, use of opioids (measured in morphine milliequivalent), and incidence of complications and adverse effects at 30 days, 60 days, and 90 days from baseline among the three treatment arms

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
45
Inclusion Criteria
  • Patients diagnosed with chronic knee pain (baseline pain score >=4), seen at Pain Management Center at MD Anderson Cancer Center; if patient has bilateral knee pain, the side with the more severe knee pain will be treated first and counted towards the primary and secondary endpoints
  • Patients between ages 18-85 years old
  • Patient signed informed consent
Exclusion Criteria
  • Patients with cognitive dysfunction or without capacity to consent
  • Patient with recent history (<6 months) of drug or alcohol abuse
  • Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection
  • Patients with allergies to local anesthesia, steroids, or adhesives
  • Patients who are on opioids for reasons other than knee pain

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Group 2 (PNS therapy plus 1 standard steroid injection).PNS therapyParticipants will receive PNS therapy plus 1 standard steroid injection.
Group 2 (PNS therapy plus 1 standard steroid injection).TriamcinoloneParticipants will receive PNS therapy plus 1 standard steroid injection.
Group 3 (PNS therapy plus 1 placebo injection)PNS therapyParticipants will receive PNS therapy plus 1 placebo injection.
Group 3 (PNS therapy plus 1 placebo injection)PlaceboParticipants will receive PNS therapy plus 1 placebo injection.
Group 1 (standard steroid injection)TriamcinoloneParticipants will receive 1 standard steroid injection.
Group 1 (standard steroid injection)BupivacaineParticipants will receive 1 standard steroid injection.
Group 2 (PNS therapy plus 1 standard steroid injection).BupivacaineParticipants will receive PNS therapy plus 1 standard steroid injection.
Primary Outcome Measures
NameTimeMethod
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 4.0through study completion; an average of 1 year
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

M D Anderson Cancer Center

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath